Hammerman, Peter S.
Novartis Institutes for BioMedical Research, Inc.,
United States
2025 Rank: 68639
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 2076 out of 355674 Researchers
Data For The Year: 2025
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 68639 | 76593 |
| Total Cites | 2513 | 2616 |
| H-index | 21 | 22 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 159 | 165 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 394 | 405 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2169 | 2243 |
| Ratio of Total Citations to Distinct Citing Papers | 1.16 | 1.17 |
| Self-Citation Percentage |
3.94%
|
|
Hammerman, Peter S.
Novartis Institutes for BioMedical Research, Inc.,
United States
2024 Rank: 51444
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1661 out of 334837 Researchers
Data For The Year: 2024
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 51444 | 56338 |
| Total Cites | 2764 | 2884 |
| H-index | 26 | 27 |
| Hm-index | 4 | 4 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 166 | 180 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 434 | 450 |
| Composite Score | 2 | 2 |
| Number of Distinct Citing Papers | 2344 | 2414 |
| Ratio of Total Citations to Distinct Citing Papers | 1.18 | 1.19 |
| Self-Citation Percentage |
4.16%
|
|
Hammerman, Peter S.
Harvard Medical School,
United States
2023 Rank: 41696
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1468 out of 312644 Researchers
Data For The Year: 2023
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 41696 | 46782 |
| Total Cites | 3370 | 3541 |
| H-index | 27 | 27 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 237 | 253 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 507 | 527 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 2800 | 2918 |
| Ratio of Total Citations to Distinct Citing Papers | 1.20 | 1.21 |
| Self-Citation Percentage |
4.83%
|
|
Hammerman, Peter S.
Harvard Medical School,
United States
2022 Rank: 31243
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1170 out of 293195 Researchers
Data For The Year: 2022
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 31243 | 34262 |
| Total Cites | 3735 | 3954 |
| H-index | 26 | 27 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 279 | 299 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 632 | 664 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3050 | 3182 |
| Ratio of Total Citations to Distinct Citing Papers | 1.22 | 1.24 |
| Self-Citation Percentage |
5.54%
|
|
Hammerman, Peter S.
Novartis Institutes for BioMedical Research, Inc.,
United States
2021 Rank: 36443
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1305 out of 271773 Researchers
Data For The Year: 2021
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 36443 | 40854 |
| Total Cites | 5563 | 5874 |
| H-index | 30 | 31 |
| Hm-index | 6 | 6 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 466 | 487 |
| Number of Single+First+Last Authored Papers | 23 | 23 |
| Total Cites to Single+First+Last Authored Papers | 993 | 1027 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 4481 | 4671 |
| Ratio of Total Citations to Distinct Citing Papers | 1.24 | 1.26 |
| Self-Citation Percentage |
5.29%
|
|
Hammerman, Peter S.
Dana-Farber Cancer Institute,
United States
2020 Rank: 35240
Overall Rank
Rank in SubField 1
Publications
Citations
Main Field:
Clinical Medicine
SubField 1:
Oncology & Carcinogenesis
SubField 2:
Immunology
Rank in SubField 1: 1232 out of 230678 Researchers
Data For The Year: 2020
| Metrics | Self-Citations Excluded | All |
|---|---|---|
| Rank Based on Composite Score | 35240 | 38656 |
| Total Cites | 3981 | 4263 |
| H-index | 25 | 25 |
| Hm-index | 5 | 5 |
| Number of Single Authored Papers | 0 | 0 |
| Total Cites to Single Authored Papers | 0 | 0 |
| Number of Single+First Authored Papers | 7 | 7 |
| Total Cites to Single+First Authored Papers | 364 | 389 |
| Number of Single+First+Last Authored Papers | 24 | 24 |
| Total Cites to Single+First+Last Authored Papers | 722 | 758 |
| Composite Score | 3 | 3 |
| Number of Distinct Citing Papers | 3177 | 3362 |
| Ratio of Total Citations to Distinct Citing Papers | 1.25 | 1.27 |
| Self-Citation Percentage |
6.62%
|
|
Related Profiles
Featured Profiles
Partner with Us
📢 Reach a targeted audience of science enthusiasts and professionals through our platform. Contact our marketing team:
business@topscinet.com cc: top2percentscientist@gmail.comGet a custom proposal tailored to your banner ad goals.
Partner with Us
📢 Partner with us and reach a targeted audience of science enthusiasts and professionals through our platform. Your company/institute’s banner could be here.